| Overview |
| bs-22306R-PE |
| TNFR1 Polyclonal Antibody, PE Conjugated |
| WB, IF |
| Human |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TNFR1 |
| Polyclonal |
| IgG |
| 1mg/ml |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7132 |
| P19438 |
| Secreted, Cell membrane |
| TNFRSF1a; CD120a; CD120a antigen; MGC19588; p55; p55 R; p55R; p60; TBP1; TBPI; TNF R; TNF R I; TNF R1; TNF R55; TNF-R1; Soluble TNF Receptor I; Soluble TNF p55 Receptor; TNF-RI; TNFR 1; TNFR I; TNFR-I; TNFR55; TNFR60; TNFRI; TNFRSF1a; TNR1A_HUMAN; Tumor necrosis factor alpha receptor; Tumor necrosis factor binding protein 1; Tumor necrosis factor receptor 1; Tumor necrosis factor receptor type 1; Tumor necrosis factor receptor type I; Tumor necrosis factor-binding protein 1. |
| Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase. |
| Application Dilution |
| WB |
=1:500-2000 |
| IF |
|
Powered by Bioz